Holen Sie sich die Stockscreener-App
1.3899
0.72%
0.0099
Ikena Oncology Inc Aktie (IKNA) Neueste Nachrichten
Ikena Oncology to implement 1-for-12 reverse stock split and rebrand as ImageneBio By Investing.com - Investing.com South Africa
Ikena Oncology Announces Reverse Stock Split and Rebrand - TipRanks
Ikena to Rebrand as ImageneBio, Start 1-for-12 Reverse Split 28 Jul 2025 | IKNA SEC FilingForm 8-K - Stock Titan
Ikena Oncology and Inmagene Biopharmaceuticals Announce - GlobeNewswire
Kristin Yarema to lead merged Inmagene-Ikena entity - biocentury.com
Ikena Oncology shares climb as Kristin Yarema named CEO of soon-to-merge ImageneBio - MSN
Ikena Oncology stock rises after naming Kristin Yarema as CEO of combined company - Investing.com India
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company - The Manila Times
Ikena Oncology and Inmagene name Kristin Yarema as CEO of combined firm By Investing.com - Investing.com South Africa
Roche-Acquired Poseida CEO Takes Helm at Ikena-Inmagene Merger with $75M Funding - Stock Titan
Ikena Oncology Inc. Stock Analysis and ForecastRemarkable growth - Autocar Professional
What analysts say about Ikena Oncology Inc. stockTriple returns potential - Autocar Professional
Ikena Oncology Announces Merger with Inmagene - TipRanks
IKNA issues special CVR dividend ahead of Inmagene merger | IKNA SEC FilingForm 8-K - Stock Titan
What drives Ikena Oncology Inc. stock priceBreakneck growth rates - jammulinksnews.com
Is Ikena Oncology Inc. a good long term investmentBreakthrough stock performance - jammulinksnews.com
Ikena Oncology Approves Merger and Reverse Stock Split - The Globe and Mail
Ikena Oncology amends executive agreement with Dr. Jotin Marango for equity vesting - Investing.com Nigeria
Ikena Oncology amends executive agreement with Dr. Jotin Marango for equity vesting By Investing.com - Investing.com South Africa
Ikena Oncology Updates Employment Terms Amid Merger Plans - TipRanks
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals - GlobeNewswire
How Ikena Oncology Inc. stock performs during market volatilityIntraday Trade Ideas - Newser
Ikena Oncology announces stockholder approval of merger with Inmagene Biopharmaceuticals - MarketScreener
Ikena shareholders approve merger with Inmagene, reverse stock split - Investing.com Australia
Ikena announces 1-for-12 reverse stock split, approval of Inmagene merger - TipRanks
Ikena shareholders approve merger with Inmagene, reverse stock split By Investing.com - Investing.com Nigeria
Ikena Oncology Approves Merger with Inmagene Biopharmaceuticals - AInvest
Ikena Oncology Shareholders Green Light Inmagene Merger: What the 1-for-12 Split Means for Investors - Stock Titan
Why Ikena Oncology Inc. stock attracts strong analyst attentionFree Best Performing Stock Alerts - Newser
What makes Ikena Oncology Inc. stock price move sharplyFree Stock Market Real-Time Monitoring - Newser
Ikena Oncology Merger Recommended by Shareholder Services - The Globe and Mail
SBET spends $25.7M on 10,000 ETH; Share-reserve waiver opens ATM issuances | IKNA SEC FilingForm 8-K - Stock Titan
Ikena Oncology Announces Support from ISS and Glass Lewis for Shareholder Vote on Inmagene Merger - Nasdaq
Ikena Oncology Announces ISS and Glass Lewis Recommend - GlobeNewswire
Ikena Oncology (NASDAQ:IKNA) Stock Price Up 1.5% – Here’s Why - Defense World
Ikena Oncology: Inmagene Begins Phase 2b Study for IMG-007 - TipRanks
Two Sigma Investments LP Sells 55,935 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Squarepoint Ops LLC Acquires Shares of 43,640 Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Millennium Management LLC Trims Stake in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Citadel Advisors LLC Lowers Position in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
3.43%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):